What's the average weight loss on Wegovy — and what affects your result?

What did the clinical trials find about average weight loss on Wegovy?

The headline figure from the STEP 1 trial, published in the New England Journal of Medicine, is an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose. For context, someone weighing 110 kg at the start would lose roughly 16–17 kg on average. Participants taking placebo lost about 2.4% over the same period, which shows how much of that result is attributable to the medicine itself rather than the lifestyle support alone.

Those averages hide real spread. Some participants lost considerably more, around one in three people in the trial lost more than 20% of their starting weight. Others lost less. An average is a useful anchor, but it is not a forecast for any individual.

The higher-dose 7.2mg Wegovy pen, approved by the MHRA on 14 April 2026, adds a new tier to the picture. Trials with that dose reported average losses of around 20.7% over 72 weeks, enough to make the gap between Wegovy and tirzepatide at its highest dose considerably smaller than earlier comparisons suggested. You can read more about how long Wegovy takes to work and what to expect across each phase of treatment.

Does the dose you reach change how much weight you lose?

Yes, meaningfully. Semaglutide follows a titration schedule (starting low and stepping up over several months) specifically to let the body adjust and reduce side effects. The 2.4mg figure from STEP 1 reflects participants reaching and sustaining that maintenance dose. People who cannot tolerate a higher dose, or who do not reach it, tend to see smaller average losses.

The titration schedule itself matters for timing too. The first few weeks at 0.25mg are essentially about tolerability rather than effect; the dose that drives the bulk of appetite suppression comes later. This is one reason weight loss in the first month looks modest compared with later stages, and why the 68-week or 72-week trial windows reflect a fuller picture than early snapshots.

One quick check worth doing: if you are tracking progress, compare your weight at the same time of day on the same day each week rather than daily, daily fluctuations from water and food make it easy to misread the trend. A simple weekly note in your phone takes under a minute and gives a far cleaner signal.

Dose availability and titration timing are always confirmed through your prescriber. Our Wegovy overview page covers the licensed schedule and what to expect at each stage.

What factors explain why results differ so much between people?

Several things interact. Duration is the most straightforward: weight loss on Wegovy accumulates over months, so someone assessed at 16 weeks and someone assessed at 68 weeks will look very different. The trial data captures a long arc that short-term experience can miss.

Biology plays a significant role too. Metabolic rate, hormonal factors and individual response to GLP-1 receptor agonism all vary. Some people find appetite drops sharply within weeks of a dose increase; others notice a more gradual shift. Neither is a sign that the medicine is or isn't working, it is just pharmacological variation.

Lifestyle factors consistently appear in the trial data as well. STEP 1 participants all received structured diet and activity support; the real-world setting without that support tends to produce somewhat smaller average losses. Adequate protein intake is particularly relevant because the appetite suppression Wegovy produces can reduce overall food volume, and protein helps preserve lean muscle mass through that reduction. Your prescriber or a dietitian can advise on practical targets.

The week-by-week pattern is also worth understanding: early weeks often show faster change partly because of water-weight shifts, with fat loss continuing more steadily afterward. The average weekly figures across the trial period help set realistic expectations for each phase.

Is Wegovy available through the NHS, or do you need to go private?

Wegovy is recommended by NICE (TA875) for use within specialist weight management services, for a maximum of two years, for adults with a BMI of 35 or above and at least one weight-related condition. NHS waiting lists for those services are commonly long, and the criteria are strict. Some people do not meet the threshold; others meet it but cannot access a service quickly.

Private treatment through a regulated online pharmacy is the practical alternative. It requires no referral and no waiting list, but it does require a proper clinical assessment, because Wegovy remains a prescription-only medicine regardless of where it is obtained. The NHS's semaglutide page sets out the medicine's licensed uses and safety profile clearly if you want the full clinical picture before a consultation.

Thinking about cost alongside results is reasonable. How those results compare across doses and over time is worth reading before making a decision. If you would like to explore whether Wegovy is clinically suitable for you, our prescribers carry out a full clinical review, the same day you submit your consultation, not by an automated process. Start your free consultation at any point.